- Home
- NUS vs TSHA Comparison
NUS vs TSHA Comparison
Compare NUS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- TSHA
- Stock Information
- Founded
- NUS 1984
- TSHA 2019
- Country
- NUS United States
- TSHA United States
- Employees
- NUS N/A
- TSHA N/A
- Industry
- NUS Other Pharmaceuticals
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- TSHA Health Care
- Exchange
- NUS Nasdaq
- TSHA Nasdaq
- Market Cap
- NUS 321.6M
- TSHA 356.7M
- IPO Year
- NUS 1996
- TSHA 2020
- Fundamental
- Price
- NUS $7.45
- TSHA $1.67
- Analyst Decision
- NUS Hold
- TSHA Strong Buy
- Analyst Count
- NUS 2
- TSHA 8
- Target Price
- NUS $6.88
- TSHA $6.63
- AVG Volume (30 Days)
- NUS 687.5K
- TSHA 1.7M
- Earning Date
- NUS 05-07-2025
- TSHA 05-13-2025
- Dividend Yield
- NUS 3.23%
- TSHA N/A
- EPS Growth
- NUS N/A
- TSHA N/A
- EPS
- NUS N/A
- TSHA N/A
- Revenue
- NUS $1,732,084,000.00
- TSHA $8,333,000.00
- Revenue This Year
- NUS N/A
- TSHA N/A
- Revenue Next Year
- NUS N/A
- TSHA N/A
- P/E Ratio
- NUS N/A
- TSHA N/A
- Revenue Growth
- NUS N/A
- TSHA N/A
- 52 Week Low
- NUS $5.95
- TSHA $1.19
- 52 Week High
- NUS $14.04
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- NUS 44.09
- TSHA 43.73
- Support Level
- NUS $7.98
- TSHA $1.59
- Resistance Level
- NUS $8.35
- TSHA $1.87
- Average True Range (ATR)
- NUS 0.33
- TSHA 0.10
- MACD
- NUS -0.09
- TSHA -0.01
- Stochastic Oscillator
- NUS 0.52
- TSHA 8.93
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.